Journal of Neurology

, 258:1708

4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation

  • Roman Schniepp
  • Max Wuehr
  • Nibal Ackl
  • Adrian Danek
  • Thomas Brandt
  • Michael Strupp
  • Klaus Jahn
Letter to the Editors

References

  1. 1.
    Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268PubMedCrossRefGoogle Scholar
  2. 2.
    Hausdorff JM (2005) Gait variability: methods, modeling and meaning. J Neuroeng Rehabil 2:19PubMedCrossRefGoogle Scholar
  3. 3.
    Hausdorff JM (2007) Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking. Hum Mov Sci 26:555–589PubMedCrossRefGoogle Scholar
  4. 4.
    Ilg W, Golla H, Thier P, Giese MA (2007) Specific influences of cerebellar dysfunctions on gait. Brain 130:786–798PubMedCrossRefGoogle Scholar
  5. 5.
    Jahn K, Deutschlander A, Stephan T, Kalla R, Wiesmann M, Strupp M, Brandt T (2008) Imaging human supraspinal locomotor centers in brainstem and cerebellum. Neuroimage 39:786–792PubMedCrossRefGoogle Scholar
  6. 6.
    Jodice C, Mantuano E, Veneziano L, Trettel F, Sabbadini G, Calandriello L, Francia A, Spadaro M, Pierelli F, Salvi F, Ophoff RA, Frants RR, Frontali M (1997) Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 6:1973–1978PubMedCrossRefGoogle Scholar
  7. 7.
    Lohle M, Schrempf W, Wolz M, Reichmann H, Storch A (2008) Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2—a video case report. Mov Disord 23:1314–1316PubMedCrossRefGoogle Scholar
  8. 8.
    Mori S, Matsuyama K, Mori F, Nakajima K (2001) Supraspinal sites that induce locomotion in the vertebrate central nervous system. Adv Neurol 87:25–40PubMedGoogle Scholar
  9. 9.
    Powell LE, Myers AM (1995) The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci 50A:M28–M34PubMedCrossRefGoogle Scholar
  10. 10.
    Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720PubMedCrossRefGoogle Scholar
  11. 11.
    Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62:1623–1625PubMedGoogle Scholar
  12. 12.
    Strupp M, Kalla R, Glasauer S, Wagner J, Hufner K, Jahn K, Brandt T (2008) Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 171:535–541PubMedCrossRefGoogle Scholar
  13. 13.
    van de Warrenburg BP, Steijns JA, Munneke M, Kremer BP, Bloem BR (2005) Falls in degenerative cerebellar ataxias. Mov Disord 20:497–500PubMedCrossRefGoogle Scholar
  14. 14.
    Walker ML, Austin AG, Banke GM, Foxx SR, Gaetano L, Gardner LA, McElhiney J, Morris K, Penn L (2007) Reference group data for the functional gait assessment. Phys Ther 87:1468–1477PubMedCrossRefGoogle Scholar
  15. 15.
    Walter JT, Alvina K, Womack MD, Chevez C, Khodakhah K (2006) Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci 9:389–397PubMedCrossRefGoogle Scholar
  16. 16.
    Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C (2005) Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing 34:614–619PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Roman Schniepp
    • 1
    • 2
  • Max Wuehr
    • 3
  • Nibal Ackl
    • 1
  • Adrian Danek
    • 1
  • Thomas Brandt
    • 2
    • 4
  • Michael Strupp
    • 1
    • 2
  • Klaus Jahn
    • 1
    • 2
  1. 1.Department of NeurologyUniversity Hospital MunichMunichGermany
  2. 2.Integrated Research and Treatment Center for Vertigo, Balance and Ocular Motor Disorders: IFB(LMU)University of MunichMunichGermany
  3. 3.Graduate School of Systemic NeurosciencesUniversity of MunichMunichGermany
  4. 4.Institute of Clinical NeurosciencesUniversity of MunichMunichGermany

Personalised recommendations